Urinary concentration of Cathepsin D as a relievable marker of preeclampsia.

Autor: Arredondo-Zapien R; Hospital General de Irapuato, México., Verdugo-Molinares MG; Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social. Guadalajara, México; Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco. Guadalajara, México., Ku Centurion M; Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social. Guadalajara, México; Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco. Guadalajara, México., Benavides-Diosdado R; Hospital General de Irapuato, México., Lopez-Rojas JF; Hospital General de Irapuato, México., Gonzalez-Gonzalez R; Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social. Guadalajara, México., Espinoza-Hernandez JA; Hospital General de Irapuato, México., Gutierrez-Chavez J; Hospital General de Irapuato, México., Cortes Sanabria L; Unidad de Investigación Biomédica 02, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, México., Melo Z; CONAHCYT-Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social. Guadalajara, México. Electronic address: zcmelo@conahcyt.mx.
Jazyk: angličtina
Zdroj: Pregnancy hypertension [Pregnancy Hypertens] 2024 Jun; Vol. 36, pp. 101116. Date of Electronic Publication: 2024 Feb 25.
DOI: 10.1016/j.preghy.2024.101116
Abstrakt: Background: The early and accurate diagnosis of preeclampsia is crucial to avoid serious complications for both the mother and baby. However, the current diagnostic methods are limited, and there is a need for new diagnostic biomarkers. Previous studies have shown that cathepsin D (CTD) participates in the pathophysiology of preeclampsia and is present in urine samples, making it a potential biomarker for the disease. This study aimed to compare urinary and serum levels of CTD in preeclamptic and normotensive women and analyze its potential role as a diagnostic biomarker in preeclampsia.
Methods: The study included thirty-nine patients with preeclampsia and twelve normotensive pregnant women as controls. Biomarkers were determined using Multiplex Assay kit, and serum prolactin (Prl) and urinary TNF-α levels were also evaluated. Statistical analysis was conducted using the Mann-Whitney U test.
Results: We found that urinary and serum CTD levels were significantly higher in the preeclampsia group than in the normotensive group, suggesting that CTD could be a diagnostic biomarker for preeclampsia. No significant differences were found in the levels of serum prolactin or urinary TNF-α between the two groups.
Conclusions: The study provides evidence that non-invasive biological samples such as urine can be used to improve new therapeutic strategies for the early management of preeclampsia.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: